Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited
May 14, 2025 15:00 HKT |  |
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
Apr 24, 2025 18:43 HKT |  |
|
君圣泰医药三项创新研究成果即将亮相2025欧肝会(EASL)
Apr 24, 2025 18:35 HKT | |
|
熊去氧胆小檗碱（HTD1801）一药多效 即将进入商业化新纪元
Apr 15, 2025 08:10 HKT | |
|
熊去氧膽小檗堿（HTD1801）一藥多效 即將進入商業化新紀元
Apr 15, 2025 08:10 HKT | |
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
Apr 15, 2025 08:00 HKT | |
|
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong
Mar 25, 2025 23:34 HKT | |
|
收入狂飙同比增长137% 多款产品蓄势以待 康希诺增长动能充沛
Mar 25, 2025 23:22 HKT | |
|
MASH疾病領域的大市場、大需求
Mar 20, 2025 11:53 HKT | |
|
MASH疾病领域的大市场、大需求
Mar 19, 2025 18:34 HKT | |
|
康哲藥業（00867）發佈2024年度業績：聚焦創新與專科突破 重塑增長動能
Mar 19, 2025 18:19 HKT |  |
|
康哲药业（00867）发布2024年度业绩：聚焦创新与专科突破 重塑增长动能
Mar 19, 2025 18:06 HKT | |
|
重磅發佈 - 君聖泰醫藥在JAMA Network Open發表熊去氧膽小檗鹼治療2型糖尿病的臨床2期研究數據 療效顯著 多重代謝獲益 市場前景廣闊
Mar 04, 2025 16:48 HKT | |
|
重磅发布 - 君圣泰医药在JAMA Network Open发表熊去氧胆小檗碱治疗2型糖尿病的临床2期研究数据 疗效显著 多重代谢获益 市场前景广阔
Mar 04, 2025 12:32 HKT | |
|
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
Mar 04, 2025 12:26 HKT | |
|
迪拜高层代表团一行参访君圣泰医药 解码中国医药创新范式
Feb 27, 2025 21:01 HKT | |
|
康哲藥業（867.HK）入選標普全球《可持續發展年鑒2025》
Feb 14, 2025 12:26 HKT | |
|
康哲药业（867.HK）入选标普全球《可持续发展年鉴2025》
Feb 14, 2025 12:11 HKT | |
|
康哲藥業（00867）獲得1類新藥長效抗IL-4Rα單抗MG-K10
Jan 26, 2025 13:14 HKT | |
|
康哲药业（00867）获得1类新药长效抗IL-4Rα单抗MG-K10
Jan 26, 2025 12:54 HKT | |
|